The brain shrinkage observed in Alzheimer’s may be prevented by semaglutide, the drug in Ozempic
ZEPHYR/Science Photo Library/Alamy
Ozempic and Wegovy are already transforming how we treat type 2 diabetes and obesity, and from next year another condition affecting millions of people worldwide might be added to the list: Alzheimer’s disease.
Two clinical trials investigating semaglutide, the drug in Ozempic and Wegovy, as a therapy for early Alzheimer’s are expected to conclude in 2025. If the results are positive, it could mark a breakthrough in treating this intractable condition.
Felecia Phillips Ollie DD (h.c.) is the inspiring leader and founder of The Equality Network LLC (TEN). With a background in coaching, travel, and a career in news, Felecia brings a unique perspective to promoting diversity and inclusion. Holding a Bachelor’s Degree in English/Communications, she is passionate about creating a more inclusive future. From graduating from Mississippi Valley State University to leading initiatives like the Washington State Department of Ecology’s Equal Employment Opportunity Program, Felecia is dedicated to making a positive impact. Join her journey on our blog as she shares insights and leads the charge for equity through The Equality Network.
